Overview
flowchart TD
companies_pfizer["Pfizer Inc"]
style companies_pfizer fill:#4fc3f7,stroke:#333,color:#000
companies_pfizer_0["Corporate History"]
companies_pfizer -->|"includes"| companies_pfizer_0
style companies_pfizer_0 fill:#81c784,stroke:#333,color:#000
companies_pfizer_1["Foundation and Early Growth 1849-1950"]
companies_pfizer -->|"includes"| companies_pfizer_1
style companies_pfizer_1 fill:#ef5350,stroke:#333,color:#000
companies_pfizer_2["Post-War Expansion 1950-2000"]
companies_pfizer -->|"includes"| companies_pfizer_2
style companies_pfizer_2 fill:#ffd54f,stroke:#333,color:#000
companies_pfizer_3["Twenty-First Century 2000-Present"]
companies_pfizer -->|"includes"| companies_pfizer_3
style companies_pfizer_3 fill:#ce93d8,stroke:#333,color:#000
companies_pfizer_4["Neuroscience Strategy"]
companies_pfizer -->|"includes"| companies_pfizer_4
style companies_pfizer_4 fill:#4fc3f7,stroke:#333,color:#000
companies_pfizer_5["Pipeline Programs"]
companies_pfizer -->|"includes"| companies_pfizer_5
style companies_pfizer_5 fill:#81c784,stroke:#333,color:#000
Pfizer Inc. is one of the world's largest pharmaceutical companies, with a legacy spanning over 175 years since its founding in 1849 by Charles Pfizer and Charles Erhart in Brooklyn, New York. Headquartered in New York City, Pfizer employs over 80,000 people worldwide and maintains a market capitalization of approximately $160 billion USD["@pfizer2023"].
...Overview
Mermaid diagram (expand to render)
Pfizer Inc. is one of the world's largest pharmaceutical companies, with a legacy spanning over 175 years since its founding in 1849 by Charles Pfizer and Charles Erhart in Brooklyn, New York. Headquartered in New York City, Pfizer employs over 80,000 people worldwide and maintains a market capitalization of approximately $160 billion USD["@pfizer2023"].
While Pfizer discontinued its internal neuroscience discovery programs in 2018, the company has strategically maintained its commitment to neurodegenerative disease research through partnerships, equity investments, and acquisitions. The most notable example is the 2022 acquisition of Biohaven Pharmaceuticals for $11.6 billion, which gave Pfizer the leading CGRP (calcitonin gene-related peptide) migraine franchise["@pfizer2022"].
Pfizer's approach to neurodegeneration reflects a broader industry trend toward external innovation, leveraging partnerships with biotechnology companies to access novel therapeutic modalities without maintaining expensive internal discovery infrastructure.
Corporate History
Foundation and Early Growth (1849-1950)
Pfizer was founded in 1849 by cousins Charles Pfizer and Charles Erhart, initially producing chemical compounds. The company gained prominence during World War I when it pioneered citric acid production using fermentation technology, a capability that later proved invaluable for antibiotic production[@pfizer].
Post-War Expansion (1950-2000)
The latter half of the 20th century saw Pfizer transform into a major pharmaceutical force:
- 1950s: Discovery of Terramycin (oxytetracycline), first truly broad-spectrum antibiotic
- 1970s: Introduction of major cardiovascular drugs
- 1990s: Blockbuster launches including Zoloft (sertraline), Lipitor (atorvastatin)
- 2000: Warner-Lambert merger
Twenty-First Century (2000-Present)
- 2003: Wyeth acquisition
- 2009: Wyeth merger completed
- 2020: COVID-19 vaccine development (Comirnaty) became world's best-selling drug
- 2022: Biohaven acquisition for migraine
- 2023: Continued pipeline diversification
Neuroscience Strategy
Following the 2018 strategic decision to discontinue internal neuroscience discovery, Pfizer's approach to neurodegenerative diseases has focused on three pillars[@pfizer2018]:
Strategic Partnerships: Collaborations with biotech companies for clinical development
Equity Investments: Pfizer Ventures invests in early-stage neurodegeneration companies
Acquisitions: Targeted acquisitions to gain access to late-stage assetsPipeline Programs
Funding
- IPO: 1940s (NYSE: PFE)
- Market Cap: ~$160B (2026)
- 2025 Revenue: $62B
- 2024 Revenue: $58B
- R&D Investment: ~$10B annually
Alzheimer's Disease Programs
| Program | Target/Mechanism | Indication | Phase | Partner |
|---------|-----------------|------------|-------|---------|
| ACI-35.030 | [Tau](/proteins/tau) phosphorylation vaccine | AD | Phase 1/2 | AC Immune |
| ACI-35.016 | Tau vaccine | AD | Phase 1 | AC Immune |
| RG6102 | Anti-tau mAb | AD | Phase 2 | Roche |
ACI-35 (with AC Immune) is a liposome-based tau vaccine designed to induce antibodies against phosphorylated tau proteins. The Phase 1/2 study is evaluating safety, immunogenicity, and biomarker effects in patients with early Alzheimer's disease[@immune].
Parkinson's Disease Programs
| Program | Target/Mechanism | Indication | Phase | Partner |
|---------|-----------------|------------|-------|---------|
| DNL151 (BIIB122) | [LRRK2](/entities/lrrk2) inhibitor | PD | Phase 1b | Denali |
| BIIB060 | LRRK2 inhibitor | PD | Phase 1 | Denali |
DNL151 (BIIB122) is a LRRK2 kinase inhibitor co-developed with Denali Therapeutics. LRRK2 (leucine-rich repeat kinase 2) mutations are among the most common genetic causes of familial Parkinson's disease, and LRRK2 hyperactivity may contribute to sporadic PD pathogenesis[@denali].
The Phase 1b study demonstrated:
- Target engagement (pLRRK2 inhibition in peripheral monocytes)
- Good safety and tolerability
- Biomarker modulation supporting continued development
Migraine Programs (Biohaven)
Following the 2022 acquisition, Pfizer gained the leading CGRP migraine franchise[@biohaven]:
| Program | Target/Mechanism | Indication | Status |
|---------|-----------------|------------|--------|
| Rimegepant (Nurtec ODT) | CGRP receptor antagonist | Acute/Preventive migraine | Approved |
| Zavegepant | CGRP receptor antagonist | Acute migraine (nasal spray) | Approved |
| Rimegepant ODT | CGRP receptor antagonist | Preventive migraine | Approved |
Rimegepant (Nurtec ODT) is the only CGRP antagonist approved for both acute and preventive migraine treatment. The drug's dual indication and oral bioavailability have made it a commercial success, with over $600 million in annual revenue[@rimegepant].
Other Neuroscience Programs
| Program | Target/Mechanism | Indication | Phase | Status |
|---------|-----------------|------------|-------|--------|
| PF-06412562 | PDE10A inhibitor | Schizophrenia | Phase 1 | Discontinued |
| PF-5198237 | 5-HT1F agonist | Acute migraine | Phase 1 | Discontinued |
Partnerships and Collaborations
AC Immune Partnership
Pfizer's partnership with AC Immune focuses on tau-targeted therapies for Alzheimer's disease[@immune]:
- ACI-35: Phosphorylated tau vaccine in Phase 1/2
- ACI-35.016: Next-generation tau vaccine
- Financial terms: $400 million upfront, $350 million milestones
Denali Therapeutics Partnership
The partnership with Denali focuses on LRRK2 inhibitors for Parkinson's disease[@denali]:
- DNL151/BIIB122: Lead program in Phase 1b
- Financial terms: $150 million equity investment (2018), $75 million upfront, $210 million milestones
Biohaven Acquisition
The 2022 acquisition of Biohaven Pharmaceuticals gave Pfizer[@pfizer2022][@biohaven]:
- Rimegepant: Dual-indication CGRP antagonist
- Zavegepant: Nasal spray formulation
- Other pipeline: TRPM3 antagonist, CGRP-related programs
- Commercial infrastructure: 600+ person specialty sales force
Pfizer Ventures
Pfizer's venture capital arm has invested in multiple neurodegeneration-focused companies:
- Denali Therapeutics: Original $150 million investment (2018)
- Vivet Therapeutics: Gene therapy for Wilson's disease
- Cortico Biosciences: Neuroinflammation platform
Clinical Evidence
Rimegepant Clinical Program
The clinical development of rimegepant demonstrated[@rimegepant]:
Acute Treatment (Phase 3):
- Primary endpoint: Pain freedom at 2 hours (21% vs 11% placebo, p<0.001)
- Key secondary: Freedom from most bothersome symptom (35% vs 27%)
Preventive Treatment (Phase 2/3):
- Primary endpoint: Reduction in monthly migraine days (-4.3 vs -2.5 placebo)
- Sustained pain relief: 49% achieved pain relief at 48 hours without rescue
LRRK2 Inhibitor Phase 1b
The DNL151 Phase 1b study demonstrated[@denali]:
- Target engagement: 50-80% inhibition of pLRRK2 in monocytes
- Safety: No serious adverse events, mild GI symptoms
- Pharmacokinetics: Supports once-daily dosing
| Year | Revenue (USD) | Key Products | R&D Spend |
|------|---------------|--------------|-----------|
| 2023 | $58.5B | Comirnaty, Paxlovid, Nurtec | $10.5B |
| 2022 | $100.3B | Comirnaty, Paxlovid | $11.4B |
| 2021 | $81.3B | Comirnaty | $10.7B |
| 2020 | $41.9B | Prevnar, Eliquis | $9.4B |
Post-COVID, Pfizer is refocusing on traditional pharmaceutical revenue streams, with the Biohaven acquisition providing growth in migraine and expanding CNS presence[@pfizer2023].
Key Personnel
- Albert Bourla (Chairman and CEO): Veterinarian by training, CEO since 2019
- Mikael Dolsten (Chief Scientific Officer): Global R&D leadership
- Angela Hwang (President, Pfizer Biopharmaceuticals)
- Aamir Malik (Chief U.S. Medical Officer)
Competitive Landscape
Alzheimer's Disease:
- Biogen/Eisai (Leqembi) - market leader
- Eli Lilly (Donanemab) - direct competitor
- Roche - failed gantenerumab
Parkinson's Disease:
- Denali/Biogen (LRRK2 inhibitors)
- Prothena (alpha-synuclein)
- Voyager Therapeutics (gene therapy)
Migraine:
- AbbVie (Ubrogepant)
- Teva (Fremanezumab)
- Amgen (Erenumab)
Pipeline Outlook (2024-2027)
| Year | Program | Milestone |
|------|---------|-----------|
| 2025 | ACI-35 | Phase 2 data expected |
| 2025 | BIIB122 | Phase 2b readout |
| 2026 | Zavegepant launch | Market expansion |
Cross-References
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Tau Pathology](/mechanisms/tau-pathology)
- [LRRK2](/genes/lrrk2)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- CGRP Receptor
- [Migraine](/diseases/migraine)
- [AC Immune](/companies/ac-immune)
- [Denali Therapeutics](/companies/denali-therapeutics)
See Also
- [SGLT2 Inhibitors for Neurodegeneration](/therapeutics/sglt2-inhibitors-neurodegeneration)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
Unknown, Pfizer Annual Report 2023 (2023)
Unknown, Pfizer Completes Biohaven Acquisition - Press Release 2022 (2022)
Unknown, Pfizer Company History (n.d.)
Unknown, Pfizer Discontinues Neuroscience Research - Reuters 2018 (2018)
Unknown, AC Immune Pipeline and Partnerships (n.d.)
[Unknown, Denali LRRK2 Program - Science Translational Medicine (n.d.)](https://pubmed.ncbi.nlm.nih.gov/33139563/)
[Unknown, Biohaven CGRP Franchise Analysis (n.d.)](https://pubmed.ncbi.nlm.nih.gov/32863207/)
[Unknown, Rimegepant Clinical Trials - Headache Journal (n.d.)](https://pubmed.ncbi.nlm.nih.gov/32863207/)